Ultime notizie per Genmab (NASDAQ:GMAB) Azioni

GENMAB A/S -SP ADR

Genmab

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS

Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.30 by 10 percent. This is a 10 percent increase over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $445.17 million which beat the analyst consensus estimate of $434.78 million by 2.39 percent. This is a 16.89 percent increase over sales of $380.85 million the same period last year.

Earnings

Earnings Beats

News

Dynatrace Q4 Adj. EPS $0.33 Beats $0.30 Estimate, Sales $445.17M Beat $434.78M Estimate

MakeMyTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.30 by 40 percent. This is a 10.53 percent increase over earnings of $0.38 per share from the same period last year. The company reported quarterly sales of $261.19 million which beat the analyst consensus estimate of $255.93 million by 2.06 percent. This is a 22.90 percent increase over sales of $212.53 million the same period last year.

MMYT

MakeMyTrip Q4 Adj. EPS $0.42 Beats $0.30 Estimate, Sales $261.19M Beat $255.93M Estimate

<ul>
<li>Potential best-in-class extrahepatic in vivo gene editing with all-in-one delivery to the central nervous system (CNS) is a critical milestone for the treatment of neurological disorders.</li>
<li>Advancements demonstrate the ability to specifically integrate correct copies of complete genes, potentially enabling treatment of any disease caused by a loss-of-function mutation.</li>
</ul>
Key highlights from the company's three poster presentations at ASGCT are below.
<a href="https://www.globenewswire.com/Tracker?data=9yX8a0siWUu86CPPpMs78hcSclIKkQlHcOyOy7e9xdpb2h3iGyDxA83ihILdBnjw1HQHaS2CbxHVuCWMTH0w57JoTAv2b3WeMSuzDqdT4CcFlapWqyMBF4OtT6sLv43f8ShQBhSCiwrTDSwnTmHHUtBm5GdndrKZibF8MLDKDxgXe-5xf4aJnbibP3g4e81XaOMuDKRa2TxPfEm_NspaTMnRTVglZpXZIVLUMECAJfmavFXTHugoE-4vOk0sHhZn">A Compact and Potent Type II CRISPR System for CNS Gene Knockdown via AAV Delivery</a>
<ul>
<li>MG21-1 is a novel, compact type II nuclease comprising 1,098 amino acids that, when delivered with its guide RNA in a single adeno-associated virus (AAV), achieved strong protein knockdown in the CNS.</li>
<li>In vivo, localized injection of AAV9 packaged with MG21-1 in the mouse motor cortex produced up to 69% target protein reduction.</li>
<li>Systemic delivery with a blood-brain barrier-crossing capsid resulted in 82% protein knockdown in the brain and 71% in the brainstem.</li>
<li>These results demonstrate the potential of a small CRISPR nuclease to efficiently knock-down targets in the CNS using a single AAV injected locally or systemically.</li>
</ul>
<a href="https://www.globenewswire.com/Tracker?data=z7WKpuXB4eDrDGOE23u9TFcEu0CtaS12WlveJxpCODdSfO_DwJU_kZyca3RZr6BtxcLv77FA7mqyYZIkfXYFn9WDK3ry-6OthXJ5TEccYich9Lr3Fay3ff-ksWEuaMaRj2k7OCHjEN_WVUht2DXoU0Sd2iAOaDWX-0YXvNCqWe1e-yRRbM52WGTYVEVDAiZ9HL4fTj4Hq8ii5qwuEM3W7Nv383eU3ORRwvJgcICl-CGZvmdc2K2t1vpd-VIe9HW6">In Vivo Genome Editing with an Ultra-Compact Type V Nuclease for All-In-One AAV Delivery&nbsp;</a>
<ul>
<li>MG119-28 is an ultra-compact engineered type V nuclease consisting of 488 amino acids and capable of efficient genome editing across multiple cultured cell tissues when delivered using a single AAV vector.</li>
<li>In vitro, this nuclease restored dystrophin protein levels by over 50% in Duchenne muscular dystrophy (DMD) model myocytes and achieved complete gene disruption at a therapeutically relevant target locus in K562 human cells.</li>
<li>In vivo, AAV9-mediated delivery to the mouse CNS via stereotactic injection resulted in up to 52% editing efficiency in olfactory bulb nuclei and produced 64% knockdown of the target protein in the motor cortex.</li>
<li>These results highlight the potential of this ultra-compact nuclease to deliver AAV-based therapeutic genome editing beyond the liver, with implications for treating neuromuscular and neurodegenerative disorders.</li>
</ul>
<a href="https://www.globenewswire.com/Tracker?data=p5HPOOwWH3cfhRJHO9Y-K3uk7xtoptN2P-I-Www9_TzyMETbO5ScRth_f3PwunltWyzUlub2CaTfszNfEAzlxwoKSwuIsbEhcgIYC3mltru5_nfj2L57QG3kXcrLSOr89Y6hBGwvvM-61OJ-F4MumqlCiRGrmlgknmdNbOlIBvFIA0jfyVANKVxcCRdzVyeL2kl2WJksw2bzP4GxvRxdRsR2oZ_HoPbbdLAesokYtn2sxntNmtcT2DHV2lEbfuxe9l_O_4uyxtR88N8PZWi-IRg_TeGk7riV6SS_fMCaKRrZLxYhSHxG73y8dVqs1mWGWboeMbl2n3WyFksBewIGcQ==">Site-Specific Integration of Therapeutic Transgenes with a Type V-K CAST System Engineered for Efficient and Targeted Human Genome Editing&nbsp;</a>
<ul>
<li>The data demonstrate that CRISPR-associated transposases (CAST) protein engineering and delivery optimization enables efficient integration of diverse cargo designs across different cell types and target loci, including with therapeutically relevant delivery approaches that are required for in vivo editing.</li>
<li>Through structure and AI-guided protein design, integration efficiency of a compact type V-K CAST system derived from uncultivated microbes was improved by &gt;50x compared with the natural system.</li>
<li>Functional activity translated to primary mammalian cells, a key step in development for human therapeutic applications.</li>
<li>These results suggest that type V-K CAST are promising systems for site-specific programmable integration of gene-sized donors for therapeutic and biotechnological development.</li>
</ul>

Biotech

Health Care

General

Metagenomi Announced The Presentation Of Three Abstracts At The American Society Of Gene & Cell Therapy Annual Meeting

LuxExperience (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUXE#NYSE">LUXE</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.01) by 700 percent. This is a 20 percent increase over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $255.01 million which beat the analyst consensus estimate of $246.70 million by 3.37 percent. This is a 0.39 percent increase over sales of $254.02 million the same period last year.

LUXE

LuxExperience Q3 Adj. EPS $0.06 Beats $(0.01) Estimate, Sales $255.01M Beat $246.70M Estimate

Tesla Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is reportedly preparing to restart the shipping of&nbsp;components from China to the&nbsp;U.S. for the production of&nbsp;its Cybercab and Semi trucks. This move follows a recent truce over tariffs between the U.S. and China.
What Happened: The tariff truce, announced on Monday, has led to a rollback of most tariffs and countermeasures, enabling Tesla to proceed with its production plans. 
Previously, Tesla had put on hold its plans to ship components from China after U.S. President Donald Trump imposed a 145% tariff on Chinese goods, a move that threatened to disrupt Tesla&#8217;s production plans for these eagerly awaited models, reported Reuters.
Tesla did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
However, a source told the publication that the situation remains fluid given the Trump administration's unpredictability. The Elon Musk-led company plans to begin trial production of the two models in October, with the goal of starting mass production by 2026. The Cybercab will be produced in Texas, while the Semi will be built in Nevada. The company is also pursuing approval to launch a robotaxi service utilizing a fleet of Cybercabs.
See Also:&nbsp;<a href="https://benzinga.com/25/05/45395189/mark-cuban-takes-a-jab-at-howard-lutnick-in-which-time-share-company-is-he-going-to-get-a-job-in-sales-at" target="_blank" rel="noreferrer noopener">Mark Cuban Takes A Jab At Howard Lutnick, &#8216;In Which Time Share Company Is He Going To Get A Job In Sales At&#8217;</a>
Why It Matters: The tariff truce comes as a relief for Tesla, which had been grappling with production challenges due to the high tariffs imposed by the Trump administration. In April, the 145% tariffs<a href="https://www.benzinga.com/25/04/44831422/donald-trumps-145-tariffs-on-china-could-disrupt-teslas-cybercab-semi-production-report"> posed</a> significant hurdles to Tesla&#8217;s production plans for the Cybercab.
Trump's tariffs, intended to support U.S. manufacturing, ended up negatively impacting his political ally, Tesla CEO Elon Musk, who has consistently advocated for free trade and opposed tariffs. In the earnings call, Tesla CFO Vaibhav Taneja said tariffs are hindering capital investments, as the company relies on equipment imports—especially from China—to expand U.S. production lines
Meanwhile, Tesla&#8217;s ambitions to launch a robotaxi service had hit a <a href="https://www.benzinga.com/25/05/45278182/elon-musks-cybercab-ambitions-face-latest-snag-teslas-robotaxi-trademark-filing-refused-by-authorities">snag earlier</a> this month when the U.S. Patent and Trademark Office refused the company&#8217;s attempt to trademark the term &#8220;Robotaxi&#8221;.
Tesla stock climbed 4.93% to close at $334.07 on Tuesday, as per data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. On a year-to-date basis, the stock slumped 11.92%.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/05/45384934/dogecoin-shiba-inu-surge-over-25-in-7-days-what-is-going-on" target="_blank" rel="noreferrer noopener">Dogecoin, Shiba Inu Surge Over 25% In 7 Days: What Is Going On? &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

TSLA

Tesla Gears Up To Restart Key Component Shipping From China For Cybercab, Semi Truck Production In US: Report

First Quarter Fiscal 2025 versus 2024
<ul>
<li>Net new centers increased 1.0% to 1,062 total centers in 45 states</li>
<li>System-wide sales of $225.9 million increased 2.1%</li>
<li>Total revenue of $51.4 million decreased 0.9%</li>
<li>Same-store sales increased 0.7%</li>
<li>GAAP net income of $2.6 million decreased 29.7%</li>
<li>Adjusted Net Income, as now defined, of $9.5 million increased 10.3%</li>
<li>Adjusted EBITDA of $18.8 million increased 7.2%</li>
</ul>

EWCZ

European Wax Center Q1 Net New Centers +1% To 1,062 Total Centers In 45 states, Same-store Sales +0.7%

Telus Announced A Strategic Partnership With GTCR To Support Last Week's Acquisition Of Workplace Options For Cash Of Approximately CAD500 Million ($350M), Net Of Assumed Debt Of Approximately CAD100 Million ($70M)

Fiscal 2025 Financial Outlook The Company reiterates the following financial outlook for fiscal year 2025:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Fiscal 2025 Outlook</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>System-Wide Sales</td>
<td>$940 million to $960 million</td>
</tr>
<tr>
<td>Total Revenue</td>
<td>$210 million to $214 million</td>
</tr>
<tr>
<td>Same-Store Sales</td>
<td>0.0% to 2.0%</td>
</tr>
<tr>
<td>Adjusted Net Income(1), as previously defined</td>
<td>$16 million to $18 million</td>
</tr>
<tr>
<td>Adjusted Net Income(1), as now defined</td>
<td>$31 million to $33 million &nbsp;</td>
</tr>
<tr>
<td>Adjusted EBITDA</td>
<td>$69 million to $71 million</td>
</tr>
</tbody>
</table>
</figure>

Guidance

European Wax Center Affirms FY2025 Sales Guidance of $210.00M-$214.00M vs $211.88M Est

European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.05 by 156 percent. This is a 28 percent increase over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $51.43 million which beat the analyst consensus estimate of $49.70 million by 3.47 percent. This is a 0.86 percent decrease over sales of $51.87 million the same period last year.

European Wax Center Q1 Adj. EPS $0.13 Beats $0.05 Estimate, Sales $51.43M Beat $49.70M Estimate

China Automotive Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAAS#NASDAQ">CAAS</a>) affirms FY2025 sales outlook from $700.00 million to $700.00 million.

CAAS

China Automotive Systems Affirms FY2025 Sales Guidance of $700.00M

China Automotive Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAAS#NASDAQ">CAAS</a>) reported quarterly earnings of $0.24 per share. This is a 11.11 percent decrease over earnings of $0.27 per share from the same period last year. The company reported $167.09 million in sales this quarter. This is a 19.87 percent increase over sales of $139.39 million the same period last year.

China Automotive Systems Q1 EPS $0.24 Down From $0.27 YoY, Sales $167.09M Up From $139.39M YoY

Boyd Group Services (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BYD#TSX">BYD</a>) reported quarterly earnings of $0.10 per share. This is a 77.27 percent decrease over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $778.32 million which missed the analyst consensus estimate of $795.25 million by 2.13 percent. This is a 1.05 percent decrease over sales of $786.55 million the same period last year.

Earnings Misses

TSX:BYD

Boyd Group Services Q1 Adj. EPS $0.10 Down From $0.44 YoY, Sales $778.32M Miss $795.25M Estimate

Ecolab Life Sciences Has Officially Opened Its New Us Bioprocessing Applications Laboratory In King Of Prussia, Pennsylvania

<a href="https://www.bloomberg.com/news/articles/2025-05-14/pony-ai-is-said-to-confidentially-file-for-hong-kong-listing?srnd=indus" title="https://www.bloomberg.com/news/articles/2025-05-14/pony-ai-is-said-to-confidentially-file-for-hong-kong-listing?srnd=indus">https://www.bloomberg.com/news/articles/2025-05-14/pony-ai-is-said-to-confidentially-file-for-hong-kong-listing?srnd=indus</a>

Rumors

PONY

Bloomberg Reported Pony AI Is Said To Confidentially File For Hong Kong Listing

Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) fell somewhat in the early hours of Wednesday, but not before reaching a nearly three-month high.
What happened: The fifth-largest cryptocurrency by market capitalization soared to $184.72, the highest it has been since Feb. 18, before easing to around $180.
SOL gained over 5% in the last 24 hours, while its trading volume dipped 4.97%.
Investments in the derivatives market also soared. Open Interest in SOL futures and options rose 9% to $7.48 billion, the highest since Jan. 23, <a href="https://www.coinglass.com/BitcoinOpenInterest">according </a>to Coinglass.
Moreover, over 63% of derivatives traders on Binance with open SOL positions were positioned long, suggesting that the rally may continue.
See Also:<a href="https://www.benzinga.com/25/04/44621245/gold-backed-cryptos-match-yellow-metals-highs-following-trumps-liberation-day-shock"> </a><a href="https://www.benzinga.com/25/05/45339966/bitcoin-creator-satoshi-nakamotos-estimated-wealth-crosses-bill-gates-amid-apex-cryptos-sharp-rebound">Bill Gates Left Behind By Satoshi Nakamoto: Bitcoin Creator&#8217;s Wealth Now Eclipses That Of Microsoft Co-Founder Amid Crypto&#8217;s Sharp Rebound</a>
Cryptocurrency trader and analyst Crypto Sensei noted that SOL was facing short-term resistance around $180.
"Now, next stop seems to be $200 on the 1-day time frame, where a pullback is expected," the analyst predicted.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24SOL&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SOL</a> Following BTC&#39;s move, SOL is showing strength even around the short term resistance area of $180 range. Now, next stop seems to be $200 on the 1-day time frame where a pullback is expected. <a href="https://t.co/eGCbek7rZ8">pic.twitter.com/eGCbek7rZ8</a>
&mdash; Crypto Sensei (@cryptosenseiXBT) <a href="https://twitter.com/cryptosenseiXBT/status/1922565778571760110?ref_src=twsrc%5Etfw">May 14, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The crucial Moving Average Convergence Divergence indicator, which compares two exponential moving averages of an asset&#8217;s price, flashed a &#8220;Buy&#8221; signal for SOL, <a href="https://in.tradingview.com/symbols/SOLUSD/technicals/">according </a>to TradingView.
On the other hand, the Commodity Channel Index, which measures the difference between the current price and the historical average price, indicated that the asset was overbought, predicting a downside.
Price Action:&nbsp; At the time of writing, SOL was exchanging hands at $177.94, up 5.05% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. 
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45339772/michael-saylor-harnesses-ai-to-drive-home-an-important-message-on-bitcoin-its-going-up-forever">Michael Saylor Harnesses AI To Drive Home An Important Message On Bitcoin: &#8216;It&#8217;s Going Up Forever&#8217;</a></li>
</ul>
Photo via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

Movers

Trading Ideas

$SOL

Solana Trades Higher Wednesday Morning — Is A $200 Breakout On The Horizon?

President Donald Trump defended Qatar&#8217;s offer of a Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) 747-8 jumbo jet reportedly valued at $400 million, dismissing critics and declaring that &#8220;only a fool would not accept this gift on behalf of our Country.&#8221;
What Happened: Former Republican presidential contender Nikki Haley swiftly criticized the arrangement, warning that &#8220;accepting gifts from foreign nations is never a good practice&#8221; and &#8220;threatens intelligence and national security.&#8221; 
Haley highlighted Qatar&#8217;s ties to terrorist organizations, adding that such an arrangement &#8220;implies the President and U.S. can be bought.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Accepting gifts from foreign nations is never a good practice. It threatens intelligence and national security. Especially when that nation supports a terrorist organization and allows those terrorist regimes to live on its soil. Regardless of how beautiful the plane may be, it…
&mdash; Nikki Haley (@NikkiHaley) <a href="https://twitter.com/NikkiHaley/status/1922266032976363701?ref_src=twsrc%5Etfw">May 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
In a statement on Truth Social, Trump emphasized the aircraft would be given to the U.S. Air Force, not to him personally, serving as a temporary Air Force One until delayed replacements arrive. 
&#8220;Why should our military, and therefore our taxpayers, be forced to pay hundreds of millions of dollars when they can get it for free&#8230;,&#8221; Trump wrote.

<figure class="wp-block-image size-large is-resized"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14052252/Screenshot-2025-05-14-at-2.52.00%E2%80%AFPM-1024x697.png" alt="" class="wp-image-914682" style="width:539px;height:auto" /><figcaption class="wp-element-caption">Source: President Donald Trump&#8217;s post on Truth Social </figcaption></figure>
Billionaire investor Bill Ackman, CEO of Pershing Square, <a href="https://x.com/BillAckman/status/1922398382737240093">questioned</a> the inconsistency, asking why it was inappropriate for the Department of Defense to accept a plane from Qatar while &#8220;elite universities accept billions from Qatar.&#8221; 
Ackman later clarified he opposed both practices. &#8220;And both have national security implications,&#8221; he added. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">To be clear, I am opposed to both.
&mdash; Bill Ackman (@BillAckman) <a href="https://twitter.com/BillAckman/status/1922398382737240093?ref_src=twsrc%5Etfw">May 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/25/05/45399438/smci-rated-outperform-by-raymond-james-amid-dominance-in-branded-ai-server-market">SMCI Stock In &#8216;Sweet Spot,&#8217; Says Raymond James — Sets $41 Price Target As AI Revenue Hits 70%</a>
Why It Matters: Former Treasury Secretary Larry Summers compared the situation to <a href="https://www.benzinga.com/25/05/45364595/trumps-qatar-plane-a-reckless-disregard-for-national-security-says-jack-reed-betrayl-of-trust-in-protecting-us-sovereignty">&#8220;banana-republic-level corruption&#8221;</a> on social media, suggesting potential tax implications and questioning why universities face scrutiny for accepting Qatari research funds while the president receives a lavish gift.
White House Press Secretary Karoline Leavitt defended the arrangement, stating the gift &#8220;<a href="https://www.benzinga.com/25/05/45340930/trumps-400-million-boeing-jet-gift-from-qatar-sparks-outcry-from-larry-summers-peter-schiff-banana-republic-level-corruption">complies with all applicable laws</a>&#8221; and emphasizing the administration&#8217;s commitment to &#8220;full transparency.&#8221; According to sources cited by ABC News, the aircraft would transfer to the Trump Presidential Library Foundation by January 2029 after Trump&#8217;s term ends.
Sen. Jack Reed (D-R.I.), <a href="https://www.benzinga.com/25/05/45364595/trumps-qatar-plane-a-reckless-disregard-for-national-security-says-jack-reed-betrayl-of-trust-in-protecting-us-sovereignty">ranking member</a> on the Senate Armed Services Committee, warned of &#8220;counterintelligence risks&#8221; from using a foreign-donated plane. 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/market-summary/25/05/45399288/kevin-oleary-lauds-robinhoods-acquisition-of-wonderfi-will-transform-cross-border-trading-no-more-outrageous-bank-fees">Kevin O&#8217;Leary Lauds Robinhood&#8217;s Acquisition Of WonderFi Will &#8216;Transform Cross-Border Trading:&#8217; &#8216;No More Outrageous Bank Fees&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Government

Politics

Opinion

As Nikki Haley Slams Trump's $400 Million Boeing Jet Gift From Qatar, Bill Ackman Cites National Security Implications: 'Only A Fool Would Not Accept This,' Says President

Astronautics company, Intuitive Machines Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>), unveiled plans for its Near Space Network Services (NSNS) program, highlighting a strategic pivot toward recurring, high-margin revenue from lunar orbit infrastructure.
What Happened: During its <a href="https://benzinga.com/25/05/45378821/intuitive-machines-q1-earnings-revenue-up-14-im-3-mission-remains-on-track-company-affirms-fy25-guidance">first quarter earnings</a> call on Tuesday, the company positioned its satellite-based relay and navigation network as a cornerstone of its long-term growth model.
&#8220;The Lunar Data Satellite constellation portion of NSNS is designed to provide secure and continuous connectivity for navigation, command, and control of spacecraft,&#8221; CEO Stephen Altemus says, adding that it will be used to serve a &#8220;wide array of customers while driving higher margin recurring revenue streams.&#8221;
See Also: <a href="https://www.benzinga.com/general/market-summary/25/05/45399940/warren-buffett-shows-how-patience-pays-98-of-his-160-billion-wealth-came-after-turning-65-thanks-the-power-of-compound-interest">Warren Buffett Shows How Patience Pays: 98% Of His $160 Billion Wealth Came After Turning 65, Thanks The Power Of &#8216;Compound Interest&#8217;</a>
Altemus says that its customers include NASA, from which it has already secured an $18 million task order under its Commercial Lunar Payload Services (CLPS) program. He also expects this infrastructure to be used by &#8220;future commercial customers operating on or around the Moon.&#8221;
The company&#8217;s CFO, Peter McGrath, said during the call that, &#8220;We're building the assets, they're capital assets that we own. And then we're going to be selling them as a service.&#8221; 
He then compared the NSNS business model to commercial satellite networks like Globalstar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#NASDAQ">GSAT</a>) or Iridium Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>), citing its potential to generate stable, service-based revenue.
The company expects to launch its first NSNS data relay satellite alongside its IM-3 lunar delivery mission in the first half of 2026.
Why It Matters: Intuitive has been dubbed one of the <a href="https://benzinga.com/general/space/25/01/42828631/exclusive-rocket-lab-intuitive-machines-redwire-or-ast-spacemobile-33-of-readers-pick-this-space-stock-for-2025">leading space stocks</a> to watch as the industry scales new heights, as the company carves out a niche for itself in Lunar exploration, becoming a critical partner for NASA&#8217;s Artemis Program. 
During its <a href="https://benzinga.com/25/05/45378821/intuitive-machines-q1-earnings-revenue-up-14-im-3-mission-remains-on-track-company-affirms-fy25-guidance">first quarter results</a> on Tuesday, Intuitive reported $62.5 million in revenue, up 14% from the prior quarter, with $272.34 million in order backlog towards the end of the quarter. 
Price Action: The stock was up 22.42% on Tuesday, trading at $11.63 per share, and is up 2.75% after hours.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="137" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14050902/Screenshot-2025-05-14-at-2.38.45-PM-1024x137.png" alt="" class="wp-image-914660" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14050902/Screenshot-2025-05-14-at-2.38.45-PM-1024x137.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14050902/Screenshot-2025-05-14-at-2.38.45-PM-300x40.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14050902/Screenshot-2025-05-14-at-2.38.45-PM-768x103.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14050902/Screenshot-2025-05-14-at-2.38.45-PM-1536x205.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14050902/Screenshot-2025-05-14-at-2.38.45-PM.png 1600w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
For more insights on the stock's score, sign up for&nbsp;<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound" target="_blank" rel="noreferrer noopener">Benzinga Edge</a>.
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45400104/elon-musk-says-mohammed-bin-salman-and-trump-were-impressed-with-tesla-optimus-as-the-humanoid-robot-danced-to-ymca">Elon Musk Says Mohammed Bin Salman And Trump Were &#8216;Impressed&#8217; With Tesla Optimus As The Humanoid Robot Danced To &#8216;YMCA&#8217;</a></li>
</ul>
Image Via Shutterstock

Equities

SPACE

GSAT

IRDM

LUNR

Intuitive Machines Plans 'Higher-Margin Recurring Revenue Streams' By Putting Satellites Around The Moon—Scores $18 Million NASA Task Order

RKLB

Rocket Lab Completes Two Earth Return Missions in Two Months, Supports Varda Space's W-3 Capsule Recovery on May 14

BlackRock Canada Declares May 2025 Cash Distributions for TSX- and Cboe-Listed Monthly iShares ETFs, Including XIU And  ETF XRB

The recent trade agreement between the&nbsp;U.K.&nbsp;and the&nbsp;U.S.&nbsp;has been met with disapproval from&nbsp;China, potentially adding more complexity to London&#8217;s ongoing efforts to rebuild its relations with Beijing.
What Happened: The trade pact, which imposes strict security measures on Britain&#8217;s steel and pharmaceutical sectors, is the first of its kind since the U.S. introduced &#8220;reciprocal tariffs&#8221; last month. China&#8217;s foreign ministry expressed that it is a &#8220;fundamental principle&#8221; that agreements between nations should not be aimed at other countries, <a href="https://www.ft.com/content/52f7be1c-e708-4b01-b486-7f189a52c842">reported</a> the Financial Times.
This situation puts London in a delicate position between the two economic powers and may further complicate the U.K. government&#8217;s efforts to rebuild ties with China. Beijing cautioned countries against trade deals with the U.S. that could harm Chinese interests, concerned that President Trump may use such agreements to push China out of supply chains.
"Co-operation between states should not be conducted against or to the detriment of the interests of third parties,"&nbsp; the Chinese foreign ministry told the publication. 
Meanwhile, Zhang Yansheng, a senior researcher at the China Academy of Macroeconomic Research, saw this as Washington&#8217;s attempt to &#8220;isolate&#8221; China. According to him, "This type of poison pill clause is actually worse than the tariffs." Yansheng urges China to discuss the matter with the U.K. without any retaliation.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/05/45384934/dogecoin-shiba-inu-surge-over-25-in-7-days-what-is-going-on" target="_blank" rel="noreferrer noopener">Dogecoin, Shiba Inu Surge Over 25% In 7 Days: What Is Going On? &#8211; Benzinga</a>
Why It Matters: This development follows the&nbsp;<a href="https://www.benzinga.com/politics/25/05/45293839/trump-starmer-strike-us-uk-trade-deal-steel-cars-beef">US-UK trade deal</a>&nbsp;that was sealed earlier this month, aimed at cutting tariffs, boosting industrial ties and securing billions in new market access. The trade agreement also entails reductions in punitive U.S. tariffs on U.K. car and steel exports, though it stops short of fully eliminating the baseline 10% tariff on British goods. Tariff relief for British products depends on the outcome of Section 232 investigations, which assess how certain imports affect U.S. national security.
However, the deal <a href="https://www.benzinga.com/25/05/45314561/trumps-uk-trade-deal-draws-criticism-from-ford-gm-stellantis-this-hurts-american-automakers-suppliers-and-auto-workers">drew criticism</a> from American automakers, including&nbsp;Ford (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) and Stellantis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>), who feared it could harm the U.S. auto industry. 
Furthermore, Chinese President Xi Jinping on Tuesday <a href="https://www.benzinga.com/markets/25/05/45374966/xi-jinping-warns-bullying-and-hegemony-will-only-result-in-self-isolation-in-first-remarks-since-us-china-tariff-suspension">warned </a>that &#8220;bullying and hegemony will only result in self-isolation,&#8221; in his first remarks since the 90-day U.S.-China tariff suspension. This statement indirectly referred to the U.S. and could be seen as a cautionary message to other nations, including the U.K.
In response to China&#8217;s criticism U.K. government stated, &nbsp;"trade and investment with China remain important to the U.K." and that it would continue &#8220;to engage pragmatically in areas that are rooted in U.K. and global interests".
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/25/05/45314762/charlie-munger-was-once-asked-why-warren-buffett-was-so-much-richer-and-replied-he-got-an-earlier-start-before-adding-why-was-albert-einstein-poorer-than-i-was" target="_blank" rel="noreferrer noopener">Charlie Munger Was Once Asked Why Warren Buffett Was So Much Richer — He Replied, &#8216;He Got An Earlier Start,&#8217; Then Added, &#8216;Why Was Albert Einstein Poorer Than I Was?&#8217; &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

STLA

China Slams UK-US Trade Pact, Finds It 'Against' Its Interests: 'This Type Of Poison Pill Clause Is Actually Worse Than The Tariffs'

Press Releases

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Comments

Genmab

Notizie

Ultime notizie per Genmab (NASDAQ:GMAB) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO